cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00012293
title: A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer

description: The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in patients with Breast cancer.
DOI: 10.13130/rd_unimi/6np0bt/nimcub
title: Giugno_1894_Pagina_023.jpg

description: Bulletin of 1894/06/06
DOI: 10.13130/rd_unimi/gsbgp1/ingcnk
title: Giugno_1889_Pagina_080.jpg

description: Bulletin of 1889/06/20
DOI: 10.13130/rd_unimi/rjrjox/dsjyox
title: Luglio_1895_Pagina_087.jpg

description: Bulletin of 1895/07/22
DOI: 10.13130/rd_unimi/v8alup/zgrf9z
title: Giugno_1891_Pagina_061.jpg

description: Bulletin of 1891/06/16
DOI: 10.25934/pr00012294
title: A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

description: A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent (≥ 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second (FEV1) at the end of 12 weeks of treatment.
DOI: 10.13130/rd_unimi/awv4gb/uokbkc
title: Giugno_1896_Pagina_018.jpg

description: Bulletin of 1896/06/05
DOI: 10.13130/rd_unimi/nsvbhr/jzzlzp
title: Giugno_1890_Pagina_065.jpg

description: Bulletin of 1890/06/17
DOI: 10.25934/pr00012295
title: A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2302) and a Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2302E1)

description: The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α agents. Patients received either secukinumab, placebo. The core study was completed. However, the extension study was terminated early (unrelated to safety) due to the results of study AIN457F2309, which indicated the efficacy of AIN457 was not comparable to the currently available RA treatment, abatacept, thus leading to closing of the AIN457 RA program.
DOI: 10.13130/rd_unimi/cbrkhv/9thrkv
title: Gennaio_1927_Pagina_055.jpg

description: Bulletin of 1927/01/14
DOI: 10.13130/rd_unimi/jvs9pt/gcvr0p
title: Giugno_1892_Pagina_039.jpg

description: Bulletin of 1892/06/10
DOI: 10.13130/rd_unimi/xu1sm0/djmwqk
title: Giugno_1893_Pagina_040.jpg

description: Bulletin of 1893/06/10
DOI: 10.25574/03191
title: Chandra X-ray Observatory ObsId 03191

description: COLLIDING GROUPS
DOI: 10.25934/pr00012296
title: A Randomized, Double-blind, Double-dummy, 4-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of Two Doses of Mometasone Furoate Delivered Via Concept1 or Twisthaler® in Adult and Adolescent Patients With Persistent Asthma

description: The purpose of this study is to compare the efficacy, safety and pharmacokinetics of Mometasone furoate delivered via Concept1 device or Twisthaler® device in adult and adolescent patients with persistent asthma.
DOI: 10.13130/rd_unimi/gsbgp1/jwqz5r
title: Giugno_1889_Pagina_081.jpg

description: Bulletin of 1889/06/21
DOI: 10.13130/rd_unimi/rjrjox/2bk3qc
title: Luglio_1895_Pagina_099.jpg

description: Bulletin of 1895/07/25
DOI: 10.13130/rd_unimi/v8alup/nzfj8o
title: Giugno_1891_Pagina_062.jpg

description: Bulletin of 1891/06/16
DOI: 10.25934/pr00012297
title: An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.

description: This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.
DOI: 10.13130/rd_unimi/6np0bt/0umd1n
title: Giugno_1894_Pagina_024.jpg

description: Bulletin of 1894/06/06
DOI: 10.13130/rd_unimi/awv4gb/yykenr
title: Giugno_1896_Pagina_019.jpg

description: Bulletin of 1896/06/05
DOI: 10.13130/rd_unimi/nsvbhr/c2c71k
title: Giugno_1890_Pagina_066.jpg

description: Bulletin of 1890/06/17
DOI: 10.25934/pr00012298
title: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion

description: Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
DOI: 10.13130/rd_unimi/cbrkhv/hudr4p
title: Gennaio_1927_Pagina_056.jpg

description: Bulletin of 1927/01/14
DOI: 10.13130/rd_unimi/jvs9pt/bhrg26
title: Giugno_1892_Pagina_040.jpg

description: Bulletin of 1892/06/10
DOI: 10.13130/rd_unimi/xu1sm0/gbak6a
title: Giugno_1893_Pagina_041.jpg

description: Bulletin of 1893/06/11
DOI: 10.25574/03192
title: Chandra X-ray Observatory ObsId 03192

description: THE INTERACTION BETWEEN CLUSTER CENTRAL RADIO SOURCES AND COOLING FLOWS
DOI: 10.25934/pr00012299
title: A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy

description: This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy.
DOI: 10.13130/rd_unimi/gsbgp1/3qxov9
title: Giugno_1889_Pagina_082.jpg

description: Bulletin of 1889/06/21
DOI: 10.13130/rd_unimi/v8alup/foguys
title: Giugno_1891_Pagina_063.jpg

description: Bulletin of 1891/06/16
DOI: 10.25934/pr00012300
title: A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of Xolair® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

description: This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite treatment according to GINA (2009) Step 4 therapy.
DOI: 10.13130/rd_unimi/6np0bt/gvempf
title: Giugno_1894_Pagina_025.jpg

description: Bulletin of 1894/06/07
DOI: 10.13130/rd_unimi/nsvbhr/9cnxti
title: Giugno_1890_Pagina_067.jpg

description: Bulletin of 1890/06/17
DOI: 10.13130/rd_unimi/rjrjox/yt8ia9
title: Luglio_1895_Pagina_103.jpg

description: Bulletin of 1895/07/26
DOI: 10.25934/pr00012301
title: An Extension to a Phase II Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

description: During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study provided that, in the opinion of the investigator, they had benefited from treatment with STI571 and there were no safety concerns.
DOI: 10.13130/rd_unimi/awv4gb/f627k4
title: Giugno_1896_Pagina_020.jpg

description: Bulletin of 1896/06/05
DOI: 10.13130/rd_unimi/xu1sm0/r4ezzy
title: Giugno_1893_Pagina_042.jpg

description: Bulletin of 1893/06/11
DOI: 10.25574/03193
title: Chandra X-ray Observatory ObsId 03193

description: THE FATE OF MATTER IN THE MODERATE COOLING FLOW CLUSTER ABELL 1991
DOI: 10.25934/pr00012302
title: A Phase III Study of STI571 Versus Interferon-α (IFN-α) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

description: The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.
DOI: 10.13130/rd_unimi/cbrkhv/hj4uec
title: Gennaio_1927_Pagina_057.jpg

description: Bulletin of 1927/01/15
DOI: 10.13130/rd_unimi/gsbgp1/kw7xz8
title: Giugno_1889_Pagina_083.jpg

description: Bulletin of 1889/06/21
DOI: 10.13130/rd_unimi/jvs9pt/18w7hf
title: Giugno_1892_Pagina_041.jpg

description: Bulletin of 1892/06/11
DOI: 10.13130/rd_unimi/rjrjox/y3471y
title: Luglio_1895_Pagina_105.jpg

description: Bulletin of 1895/07/27
DOI: 10.13130/rd_unimi/v8alup/ycp8ij
title: Giugno_1891_Pagina_064.jpg

description: Bulletin of 1891/06/16
DOI: 10.25934/pr00012303
title: A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study

description: The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.
DOI: 10.25934/pr00012304
title: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion

description: Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 gene (SMN1) with one or two copies of survival motor neuron 2 gene (SMN2). Up to 30 patients \< 6 months (\< 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.
DOI: 10.13130/rd_unimi/6np0bt/0jf4wb
title: Giugno_1894_Pagina_026.jpg

description: Bulletin of 1894/06/07
DOI: 10.13130/rd_unimi/nsvbhr/jsbhsm
title: Giugno_1890_Pagina_068.jpg

description: Bulletin of 1890/06/17
DOI: 10.25934/pr00012305
title: Safety and Efficacy Study of ESBA1008 Versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration

description: The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative age-related macular degeneration (AMD).
DOI: 10.13130/rd_unimi/awv4gb/de2oov
title: Giugno_1896_Pagina_021.jpg

description: Bulletin of 1896/06/06
DOI: 10.13130/rd_unimi/xu1sm0/srbmap
title: Giugno_1893_Pagina_043.jpg

description: Bulletin of 1893/06/11
DOI: 10.25574/03194
title: Chandra X-ray Observatory ObsId 03194

description: CHANDRA AND HST OBSERVATIONS OF THE BRIGHTEST, RELAXED CLUSTER LENSES
DOI: 10.25934/pr00012306
title: A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration

description: The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA® in the treatment of exudative age-related macular degeneration.
DOI: 10.13130/rd_unimi/cbrkhv/12bofx
title: Gennaio_1927_Pagina_058.jpg

description: Bulletin of 1927/01/15
DOI: 10.13130/rd_unimi/gsbgp1/fb5lu0
title: Giugno_1889_Pagina_084.jpg

description: Bulletin of 1889/06/21
DOI: 10.13130/rd_unimi/jvs9pt/x1o8kf
title: Giugno_1892_Pagina_042.jpg

description: Bulletin of 1892/06/11
DOI: 10.25934/pr00012307
title: A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration

description: The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
DOI: 10.13130/rd_unimi/nsvbhr/clj8ze
title: Giugno_1890_Pagina_069.jpg

description: Bulletin of 1890/06/18
DOI: 10.13130/rd_unimi/rjrjox/d76jym
title: Luglio_1895_Pagina_106.jpg

description: Bulletin of 1895/07/27
DOI: 10.13130/rd_unimi/v8alup/zl1i5u
title: Giugno_1891_Pagina_065.jpg

description: Bulletin of 1891/06/17
DOI: 10.25934/pr00012308
title: A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration

description: The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of 3 intravitreal injections in subjects with neovascular age-related macular degeneration (AMD).
DOI: 10.13130/rd_unimi/6np0bt/uycgr3
title: Giugno_1894_Pagina_027.jpg

description: Bulletin of 1894/06/07
DOI: 10.13130/rd_unimi/awv4gb/chpyzu
title: Giugno_1896_Pagina_022.jpg

description: Bulletin of 1896/06/06
DOI: 10.13130/rd_unimi/xu1sm0/lovsbh
title: Giugno_1893_Pagina_044.jpg

description: Bulletin of 1893/06/11
DOI: 10.25574/03195
title: Chandra X-ray Observatory ObsId 03195

description: CHANDRA AND HST OBSERVATIONS OF THE BRIGHTEST, RELAXED CLUSTER LENSES
DOI: 10.25934/pr00012309
title: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration

description: The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
DOI: 10.13130/rd_unimi/cbrkhv/zxm3es
title: Gennaio_1927_Pagina_059.jpg

description: Bulletin of 1927/01/15
DOI: 10.13130/rd_unimi/gsbgp1/nblqho
title: Giugno_1889_Pagina_085.jpg

description: Bulletin of 1889/06/22
DOI: 10.13130/rd_unimi/v8alup/gphgba
title: Giugno_1891_Pagina_066.jpg

description: Bulletin of 1891/06/17
DOI: 10.25934/pr00012310
title: A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study

description: The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301 (also known as CRTH258-C002). The medical condition treated in the core and extension trials was neo-vascular age-related macular degeneration (nAMD).
DOI: 10.13130/rd_unimi/jvs9pt/iq6zk1
title: Giugno_1892_Pagina_043.jpg

description: Bulletin of 1892/06/11
DOI: 10.13130/rd_unimi/nsvbhr/0zn7ee
title: Giugno_1890_Pagina_070.jpg

description: Bulletin of 1890/06/18
DOI: 10.13130/rd_unimi/rjrjox/tqzayp
title: Luglio_1895_Pagina_107.jpg

description: Bulletin of 1895/07/27
DOI: 10.25934/pr00012311
title: A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration

description: The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
DOI: 10.13130/rd_unimi/6np0bt/efzwp9
title: Giugno_1894_Pagina_028.jpg

description: Bulletin of 1894/06/07
DOI: 10.13130/rd_unimi/awv4gb/h29m1u
title: Giugno_1896_Pagina_023.jpg

description: Bulletin of 1896/06/06
DOI: 10.13130/rd_unimi/xu1sm0/mjymws
title: Giugno_1893_Pagina_045.jpg

description: Bulletin of 1893/06/12
DOI: 10.25574/03196
title: Chandra X-ray Observatory ObsId 03196

description: OBSERVATION OF MACS CLUSTERS, Z&gt;0.5
DOI: 10.25934/pr00012312
title: A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises

description: The purpose of this study was to determine whether the investigational drug SelG1 when given to sickle cell disease patients either taking or not taking hydroxyurea was effective in preventing or reducing the occurrence of pain crises. SelG1 prevents various cells in the bloodstream from sticking together. By stopping these cell-cell interactions, SelG1 may prevent small blood vessels from becoming blocked and therefore reduce the occurrence and severity of pain crises. Other effects of SelG1 was evaluated, as well as the safety of the drug and how long it stayed in the blood stream.Funding Source - FDA Office of Orphan Products Development (OOPD)
DOI: 10.13130/rd_unimi/cbrkhv/c1u3oi
title: Gennaio_1927_Pagina_060.jpg

description: Bulletin of 1927/01/15
DOI: 10.13130/rd_unimi/gsbgp1/jucx6g
title: Giugno_1889_Pagina_086.jpg

description: Bulletin of 1889/06/22
DOI: 10.13130/rd_unimi/v8alup/wxr85s
title: Giugno_1891_Pagina_067.jpg

description: Bulletin of 1891/06/17
DOI: 10.25934/pr00012313
title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.

description: This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations:* patient with inadequately controlled severe asthma and high eosinophil counts at baseline (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population)* patients with inadequately controlled severe asthma (overall study population)Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016).
DOI: 10.13130/rd_unimi/6np0bt/v3c2qz
title: Giugno_1894_Pagina_029.jpg

description: Bulletin of 1894/06/08
DOI: 10.13130/rd_unimi/nsvbhr/k17ubf
title: Giugno_1890_Pagina_071.jpg

description: Bulletin of 1890/06/18
DOI: 10.25934/pr00012314
title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.

description: This study aimed to determine the efficacy and safety of QAW039 and QAW039 450 mg compared to placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations:* patient with inadequately controlled severe asthma and high eosinophil counts (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population)* patients with inadequately controlled severe asthma (overall study population) Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016)
DOI: 10.13130/rd_unimi/awv4gb/ulme4j
title: Giugno_1896_Pagina_024.jpg

description: Bulletin of 1896/06/06
DOI: 10.13130/rd_unimi/jvs9pt/glokjc
title: Giugno_1892_Pagina_044.jpg

description: Bulletin of 1892/06/11
DOI: 10.13130/rd_unimi/rjrjox/49kvf9
title: Luglio_1895_Pagina_096.jpg

description: Bulletin of 1895/07/24
DOI: 10.25574/03197
title: Chandra X-ray Observatory ObsId 03197

description: OBSERVATION OF MACS CLUSTERS, Z&gt;0.5
DOI: 10.25934/pr00012315
title: A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.

description: This was a three-arm, randomized, open label, multi-center phase II study investigating the combination of everolimus (10mg daily) with exemestane (25mg daily) versus everolimus (10mg daily) versus capecitabine (1250mg/m2 twice daily for 14 days, 3-week cycle) in patients with estrogen-receptor positive, HER2 negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole.
DOI: 10.13130/rd_unimi/cbrkhv/zuuibv
title: Gennaio_1927_Pagina_061.jpg

description: Bulletin of 1927/01/16
DOI: 10.13130/rd_unimi/xu1sm0/7ea958
title: Giugno_1893_Pagina_046.jpg

description: Bulletin of 1893/06/12
DOI: 10.25934/pr00012316
title: An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy

description: The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria that measures tumor size called Response Evaluation Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the patient or investigator requested discontinuation of treatment.
DOI: 10.13130/rd_unimi/6np0bt/h6mtha
title: Giugno_1894_Pagina_030.jpg

description: Bulletin of 1894/06/08
DOI: 10.13130/rd_unimi/nsvbhr/vxdvft
title: Giugno_1890_Pagina_072.jpg

description: Bulletin of 1890/06/18
DOI: 10.13130/rd_unimi/v8alup/halghu
title: Giugno_1891_Pagina_068.jpg

description: Bulletin of 1891/06/17
DOI: 10.25934/pr00012317
title: A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo

description: The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
DOI: 10.13130/rd_unimi/gsbgp1/7kxsj5
title: Giugno_1889_Pagina_087.jpg

description: Bulletin of 1889/06/22
DOI: 10.13130/rd_unimi/jvs9pt/wnurwm
title: Giugno_1892_Pagina_045.jpg

description: Bulletin of 1892/06/12
DOI: 10.13130/rd_unimi/rjrjox/eyonso
title: Luglio_1895_Pagina_109.jpg

description: Bulletin of 1895/07/28
DOI: 10.25574/03198
title: Chandra X-ray Observatory ObsId 03198

description: OBSERVATION OF MACS CLUSTERS, Z&gt;0.5